AERRANE

This brand name is authorized in Estonia, Spain, France, Hong Kong, New Zealand, Poland, Romania, Singapore, Tunisia, United Kingdom, South Africa

Active ingredients

The drug AERRANE contains one active pharmaceutical ingredient (API):

1 Isoflurane
UNII CYS9AKD70P - ISOFLURANE

Isoflurane is a general inhalational anaesthetic for use in induction and maintenance. Isoflurane provides rapid induction of anaesthesia and also rapid recovery.

Isoflurane is a fluorinated ether with general anesthetic and muscle relaxant activities. Although the exact mechanism of action has not been established, inhaled isoflurane, appears to act on the lipid matrix of the neuronal cell membrane, which results in disruption of neuronal transmission. This agent enhances the release of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA), thereby increasing the activity of the inhibitory neurotransmitter on synaptic transmission. Isoflurane may also both inhibit glutamatergic excitatory transmission by increasing glutamate re-uptake, and potentiate glycine receptor activity, which decreases motor function. In addition, isoflurane may alter certain pro- and anti-inflammatory cytokines, including interleukin-6 and -10 (IL-6, IL-10), possibly through the activation of the nuclear factor kappa B (NF-KB) pathway, which may affect immune responses during surgery.

Read about Isoflurane

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
AERRANE Liquid for inhalation Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
N01AB06 Isoflurane N Nervous system → N01 Anesthetics → N01A Anesthetics, general → N01AB Halogenated hydrocarbons
Discover more medicines within N01AB06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: EE Ravimiamet Identifier(s): 1024175, 1074372
Country: ES Centro de información online de medicamentos de la AEMPS Identifier(s): 60378
Country: FR Base de données publique des médicaments Identifier(s): 63498500
Country: GB Medicines & Healthcare Products Regulatory Agency Identifier(s): 60018
Country: HK Department of Health Drug Office Identifier(s): 50667
Country: NZ Medicines and Medical Devices Safety Authority Identifier(s): 3904
Country: PL Rejestru Produktów Leczniczych Identifier(s): 100110464
Country: RO Agenția Națională a Medicamentului și a Dispozitivelor Medicale Identifier(s): W43418001, W43418002
Country: SG Health Sciences Authority Identifier(s): 08670P
Country: TN Direction de la Pharmacie et du Médicament Identifier(s): 10153011H
Country: ZA Health Products Regulatory Authority Identifier(s): 31/2.1/0341

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.